nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—ADRA2C—Methamphetamine—obesity	0.162	0.237	CbGbCtD
Brimonidine—ADRA2B—Methamphetamine—obesity	0.154	0.225	CbGbCtD
Brimonidine—ADRA2A—Benzphetamine—obesity	0.134	0.196	CbGbCtD
Brimonidine—ADRA2A—Phenylpropanolamine—obesity	0.128	0.187	CbGbCtD
Brimonidine—ADRA2A—Methamphetamine—obesity	0.107	0.156	CbGbCtD
Brimonidine—AOX1—gall bladder—obesity	0.00111	0.147	CbGeAlD
Brimonidine—AOX1—islet of Langerhans—obesity	0.000729	0.0966	CbGeAlD
Brimonidine—Clonidine—SLC22A1—obesity	0.000659	1	CrCbGaD
Brimonidine—AOX1—adrenal cortex—obesity	0.000578	0.0766	CbGeAlD
Brimonidine—Acne—Topiramate—obesity	0.000488	0.00275	CcSEcCtD
Brimonidine—Dizziness—Phendimetrazine—obesity	0.000482	0.00272	CcSEcCtD
Brimonidine—Tachycardia—Cimetidine—obesity	0.000482	0.00272	CcSEcCtD
Brimonidine—Arthritis—Bupropion—obesity	0.000481	0.00271	CcSEcCtD
Brimonidine—Influenza—Orlistat—obesity	0.000479	0.0027	CcSEcCtD
Brimonidine—Lethargy—Bupropion—obesity	0.000477	0.00269	CcSEcCtD
Brimonidine—Nausea—Benzphetamine—obesity	0.000475	0.00268	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Diethylpropion—obesity	0.000472	0.00266	CcSEcCtD
Brimonidine—Insomnia—Diethylpropion—obesity	0.000469	0.00265	CcSEcCtD
Brimonidine—Osteoarthritis—Bupropion—obesity	0.000468	0.00264	CcSEcCtD
Brimonidine—AOX1—pituitary gland—obesity	0.000467	0.0619	CbGeAlD
Brimonidine—Vasodilation procedure—Topiramate—obesity	0.000467	0.00263	CcSEcCtD
Brimonidine—Vasodilation—Topiramate—obesity	0.000467	0.00263	CcSEcCtD
Brimonidine—AOX1—adipose tissue—obesity	0.000465	0.0616	CbGeAlD
Brimonidine—Influenza—Sibutramine—obesity	0.000464	0.00261	CcSEcCtD
Brimonidine—Dyspnoea—Diethylpropion—obesity	0.000462	0.00261	CcSEcCtD
Brimonidine—Somnolence—Diethylpropion—obesity	0.000461	0.0026	CcSEcCtD
Brimonidine—Hypersensitivity—Phenylpropanolamine—obesity	0.000459	0.00259	CcSEcCtD
Brimonidine—Headache—Phendimetrazine—obesity	0.000457	0.00258	CcSEcCtD
Brimonidine—Dyspepsia—Diethylpropion—obesity	0.000456	0.00257	CcSEcCtD
Brimonidine—Face oedema—Bupropion—obesity	0.000451	0.00255	CcSEcCtD
Brimonidine—Arthropathy—Topiramate—obesity	0.000451	0.00255	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Cimetidine—obesity	0.00045	0.00254	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Diethylpropion—obesity	0.000448	0.00253	CcSEcCtD
Brimonidine—Bronchitis—Sibutramine—obesity	0.000446	0.00251	CcSEcCtD
Brimonidine—Lacrimation increased—Topiramate—obesity	0.000445	0.00251	CcSEcCtD
Brimonidine—Somnolence—Cimetidine—obesity	0.000439	0.00247	CcSEcCtD
Brimonidine—AOX1—digestive system—obesity	0.000438	0.058	CbGeAlD
Brimonidine—Nausea—Phendimetrazine—obesity	0.000433	0.00244	CcSEcCtD
Brimonidine—Dry skin—Bupropion—obesity	0.000429	0.00242	CcSEcCtD
Brimonidine—Asthenia—Phentermine—obesity	0.000428	0.00241	CcSEcCtD
Brimonidine—Depression—Orlistat—obesity	0.000426	0.0024	CcSEcCtD
Brimonidine—Fatigue—Cimetidine—obesity	0.000425	0.0024	CcSEcCtD
Brimonidine—Nasopharyngitis—Bupropion—obesity	0.000418	0.00236	CcSEcCtD
Brimonidine—AOX1—adrenal gland—obesity	0.000417	0.0553	CbGeAlD
Brimonidine—Depression—Sibutramine—obesity	0.000412	0.00232	CcSEcCtD
Brimonidine—Dizziness—Phenylpropanolamine—obesity	0.000412	0.00232	CcSEcCtD
Brimonidine—Influenza—Bupropion—obesity	0.000404	0.00228	CcSEcCtD
Brimonidine—Conjunctivitis—Sibutramine—obesity	0.000402	0.00227	CcSEcCtD
Brimonidine—Sinusitis—Orlistat—obesity	0.000401	0.00226	CcSEcCtD
Brimonidine—Dizziness—Phentermine—obesity	0.000394	0.00222	CcSEcCtD
Brimonidine—Rash—Phenylpropanolamine—obesity	0.000393	0.00222	CcSEcCtD
Brimonidine—Dermatitis—Phenylpropanolamine—obesity	0.000392	0.00221	CcSEcCtD
Brimonidine—Bronchitis—Bupropion—obesity	0.000389	0.00219	CcSEcCtD
Brimonidine—Sinusitis—Sibutramine—obesity	0.000388	0.00219	CcSEcCtD
Brimonidine—Photophobia—Topiramate—obesity	0.000385	0.00217	CcSEcCtD
Brimonidine—Pharyngitis—Orlistat—obesity	0.000381	0.00215	CcSEcCtD
Brimonidine—Dry eye—Topiramate—obesity	0.000379	0.00214	CcSEcCtD
Brimonidine—Bradycardia—Sibutramine—obesity	0.000378	0.00213	CcSEcCtD
Brimonidine—Rash—Phentermine—obesity	0.000376	0.00212	CcSEcCtD
Brimonidine—Dermatitis—Phentermine—obesity	0.000375	0.00212	CcSEcCtD
Brimonidine—Headache—Phentermine—obesity	0.000373	0.00211	CcSEcCtD
Brimonidine—Rhinitis—Sibutramine—obesity	0.000372	0.0021	CcSEcCtD
Brimonidine—Nausea—Phenylpropanolamine—obesity	0.00037	0.00209	CcSEcCtD
Brimonidine—Pharyngitis—Sibutramine—obesity	0.000368	0.00208	CcSEcCtD
Brimonidine—ADRA2A—islet of Langerhans—obesity	0.000368	0.0487	CbGeAlD
Brimonidine—ADRA2C—adrenal cortex—obesity	0.000365	0.0484	CbGeAlD
Brimonidine—Hypersensitivity—Cimetidine—obesity	0.000364	0.00205	CcSEcCtD
Brimonidine—AOX1—endocrine gland—obesity	0.000362	0.0479	CbGeAlD
Brimonidine—Abnormal vision—Topiramate—obesity	0.000358	0.00202	CcSEcCtD
Brimonidine—Visual impairment—Sibutramine—obesity	0.000358	0.00202	CcSEcCtD
Brimonidine—Nausea—Phentermine—obesity	0.000354	0.002	CcSEcCtD
Brimonidine—Asthenia—Cimetidine—obesity	0.000354	0.002	CcSEcCtD
Brimonidine—Conjunctivitis—Bupropion—obesity	0.00035	0.00198	CcSEcCtD
Brimonidine—Eye disorder—Sibutramine—obesity	0.000347	0.00196	CcSEcCtD
Brimonidine—Immune system disorder—Orlistat—obesity	0.000346	0.00195	CcSEcCtD
Brimonidine—Mediastinal disorder—Orlistat—obesity	0.000346	0.00195	CcSEcCtD
Brimonidine—Dizziness—Diethylpropion—obesity	0.000343	0.00193	CcSEcCtD
Brimonidine—Diabetes mellitus—Topiramate—obesity	0.000343	0.00193	CcSEcCtD
Brimonidine—Sinusitis—Bupropion—obesity	0.000338	0.00191	CcSEcCtD
Brimonidine—Angiopathy—Sibutramine—obesity	0.000337	0.0019	CcSEcCtD
Brimonidine—Mental disorder—Orlistat—obesity	0.000336	0.00189	CcSEcCtD
Brimonidine—Immune system disorder—Sibutramine—obesity	0.000335	0.00189	CcSEcCtD
Brimonidine—Arrhythmia—Sibutramine—obesity	0.000331	0.00187	CcSEcCtD
Brimonidine—Eye pain—Topiramate—obesity	0.00033	0.00186	CcSEcCtD
Brimonidine—Nasal congestion—Topiramate—obesity	0.000327	0.00184	CcSEcCtD
Brimonidine—Rash—Diethylpropion—obesity	0.000327	0.00184	CcSEcCtD
Brimonidine—Dysgeusia—Orlistat—obesity	0.000327	0.00184	CcSEcCtD
Brimonidine—Dermatitis—Diethylpropion—obesity	0.000327	0.00184	CcSEcCtD
Brimonidine—Dizziness—Cimetidine—obesity	0.000326	0.00184	CcSEcCtD
Brimonidine—AOX1—liver—obesity	0.000326	0.0432	CbGeAlD
Brimonidine—Headache—Diethylpropion—obesity	0.000325	0.00183	CcSEcCtD
Brimonidine—Rhinitis—Bupropion—obesity	0.000324	0.00183	CcSEcCtD
Brimonidine—Pharyngitis—Bupropion—obesity	0.000321	0.00181	CcSEcCtD
Brimonidine—Dysgeusia—Sibutramine—obesity	0.000316	0.00178	CcSEcCtD
Brimonidine—Vision blurred—Orlistat—obesity	0.000315	0.00177	CcSEcCtD
Brimonidine—Visual disturbance—Topiramate—obesity	0.000314	0.00177	CcSEcCtD
Brimonidine—Visual impairment—Bupropion—obesity	0.000312	0.00176	CcSEcCtD
Brimonidine—Rash—Cimetidine—obesity	0.000311	0.00175	CcSEcCtD
Brimonidine—Dermatitis—Cimetidine—obesity	0.000311	0.00175	CcSEcCtD
Brimonidine—Headache—Cimetidine—obesity	0.000309	0.00174	CcSEcCtD
Brimonidine—Nausea—Diethylpropion—obesity	0.000308	0.00174	CcSEcCtD
Brimonidine—Vision blurred—Sibutramine—obesity	0.000304	0.00172	CcSEcCtD
Brimonidine—Lethargy—Topiramate—obesity	0.000304	0.00171	CcSEcCtD
Brimonidine—Eye disorder—Bupropion—obesity	0.000302	0.00171	CcSEcCtD
Brimonidine—Cardiac disorder—Bupropion—obesity	0.0003	0.00169	CcSEcCtD
Brimonidine—Flushing—Bupropion—obesity	0.0003	0.00169	CcSEcCtD
Brimonidine—Osteoarthritis—Topiramate—obesity	0.000298	0.00168	CcSEcCtD
Brimonidine—ADRA2C—pituitary gland—obesity	0.000295	0.0391	CbGeAlD
Brimonidine—Palpitations—Orlistat—obesity	0.000295	0.00166	CcSEcCtD
Brimonidine—ADRA2C—adipose tissue—obesity	0.000294	0.0389	CbGeAlD
Brimonidine—Angiopathy—Bupropion—obesity	0.000293	0.00166	CcSEcCtD
Brimonidine—Nausea—Cimetidine—obesity	0.000293	0.00165	CcSEcCtD
Brimonidine—Immune system disorder—Bupropion—obesity	0.000292	0.00165	CcSEcCtD
Brimonidine—Mediastinal disorder—Bupropion—obesity	0.000292	0.00164	CcSEcCtD
Brimonidine—Cough—Orlistat—obesity	0.000291	0.00164	CcSEcCtD
Brimonidine—Syncope—Sibutramine—obesity	0.00029	0.00163	CcSEcCtD
Brimonidine—Arrhythmia—Bupropion—obesity	0.000289	0.00163	CcSEcCtD
Brimonidine—Face oedema—Topiramate—obesity	0.000288	0.00162	CcSEcCtD
Brimonidine—Palpitations—Sibutramine—obesity	0.000285	0.00161	CcSEcCtD
Brimonidine—Chest pain—Orlistat—obesity	0.000284	0.0016	CcSEcCtD
Brimonidine—Myalgia—Orlistat—obesity	0.000284	0.0016	CcSEcCtD
Brimonidine—Loss of consciousness—Sibutramine—obesity	0.000284	0.0016	CcSEcCtD
Brimonidine—Mental disorder—Bupropion—obesity	0.000283	0.0016	CcSEcCtD
Brimonidine—Anxiety—Orlistat—obesity	0.000283	0.0016	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000282	0.00159	CcSEcCtD
Brimonidine—Cough—Sibutramine—obesity	0.000282	0.00159	CcSEcCtD
Brimonidine—Discomfort—Orlistat—obesity	0.000281	0.00158	CcSEcCtD
Brimonidine—Hypertension—Sibutramine—obesity	0.000279	0.00157	CcSEcCtD
Brimonidine—Dry mouth—Orlistat—obesity	0.000278	0.00157	CcSEcCtD
Brimonidine—Dysgeusia—Bupropion—obesity	0.000276	0.00156	CcSEcCtD
Brimonidine—Myalgia—Sibutramine—obesity	0.000275	0.00155	CcSEcCtD
Brimonidine—Chest pain—Sibutramine—obesity	0.000275	0.00155	CcSEcCtD
Brimonidine—Arthralgia—Sibutramine—obesity	0.000275	0.00155	CcSEcCtD
Brimonidine—Anxiety—Sibutramine—obesity	0.000274	0.00155	CcSEcCtD
Brimonidine—Oedema—Orlistat—obesity	0.000272	0.00154	CcSEcCtD
Brimonidine—Discomfort—Sibutramine—obesity	0.000272	0.00153	CcSEcCtD
Brimonidine—Infection—Orlistat—obesity	0.000271	0.00153	CcSEcCtD
Brimonidine—Dry mouth—Sibutramine—obesity	0.000269	0.00152	CcSEcCtD
Brimonidine—Nervous system disorder—Orlistat—obesity	0.000267	0.00151	CcSEcCtD
Brimonidine—Nasopharyngitis—Topiramate—obesity	0.000266	0.0015	CcSEcCtD
Brimonidine—Vision blurred—Bupropion—obesity	0.000265	0.0015	CcSEcCtD
Brimonidine—Skin disorder—Orlistat—obesity	0.000265	0.00149	CcSEcCtD
Brimonidine—ADRA2C—adrenal gland—obesity	0.000264	0.0349	CbGeAlD
Brimonidine—Oedema—Sibutramine—obesity	0.000264	0.00149	CcSEcCtD
Brimonidine—Infection—Sibutramine—obesity	0.000262	0.00148	CcSEcCtD
Brimonidine—Shock—Sibutramine—obesity	0.000259	0.00146	CcSEcCtD
Brimonidine—Tachycardia—Sibutramine—obesity	0.000257	0.00145	CcSEcCtD
Brimonidine—Skin disorder—Sibutramine—obesity	0.000256	0.00144	CcSEcCtD
Brimonidine—Syncope—Bupropion—obesity	0.000253	0.00142	CcSEcCtD
Brimonidine—Palpitations—Bupropion—obesity	0.000249	0.0014	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Orlistat—obesity	0.000248	0.0014	CcSEcCtD
Brimonidine—Bronchitis—Topiramate—obesity	0.000248	0.0014	CcSEcCtD
Brimonidine—Loss of consciousness—Bupropion—obesity	0.000248	0.0014	CcSEcCtD
Brimonidine—Insomnia—Orlistat—obesity	0.000246	0.00139	CcSEcCtD
Brimonidine—Hypotension—Sibutramine—obesity	0.000246	0.00139	CcSEcCtD
Brimonidine—Cough—Bupropion—obesity	0.000246	0.00139	CcSEcCtD
Brimonidine—Paraesthesia—Orlistat—obesity	0.000245	0.00138	CcSEcCtD
Brimonidine—Hypertension—Bupropion—obesity	0.000243	0.00137	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Sibutramine—obesity	0.00024	0.00135	CcSEcCtD
Brimonidine—Dyspepsia—Orlistat—obesity	0.00024	0.00135	CcSEcCtD
Brimonidine—Myalgia—Bupropion—obesity	0.00024	0.00135	CcSEcCtD
Brimonidine—Arthralgia—Bupropion—obesity	0.00024	0.00135	CcSEcCtD
Brimonidine—Chest pain—Bupropion—obesity	0.00024	0.00135	CcSEcCtD
Brimonidine—Anxiety—Bupropion—obesity	0.000239	0.00135	CcSEcCtD
Brimonidine—Insomnia—Sibutramine—obesity	0.000238	0.00134	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000238	0.00134	CcSEcCtD
Brimonidine—Discomfort—Bupropion—obesity	0.000237	0.00134	CcSEcCtD
Brimonidine—Paraesthesia—Sibutramine—obesity	0.000237	0.00134	CcSEcCtD
Brimonidine—ADRA2A—pituitary gland—obesity	0.000236	0.0312	CbGeAlD
Brimonidine—Gastrointestinal disorder—Orlistat—obesity	0.000235	0.00133	CcSEcCtD
Brimonidine—Dyspnoea—Sibutramine—obesity	0.000235	0.00133	CcSEcCtD
Brimonidine—Fatigue—Orlistat—obesity	0.000235	0.00132	CcSEcCtD
Brimonidine—ADRA2A—adipose tissue—obesity	0.000235	0.0311	CbGeAlD
Brimonidine—Dry mouth—Bupropion—obesity	0.000234	0.00132	CcSEcCtD
Brimonidine—Somnolence—Sibutramine—obesity	0.000234	0.00132	CcSEcCtD
Brimonidine—Pain—Orlistat—obesity	0.000233	0.00131	CcSEcCtD
Brimonidine—Dyspepsia—Sibutramine—obesity	0.000232	0.00131	CcSEcCtD
Brimonidine—Oedema—Bupropion—obesity	0.00023	0.0013	CcSEcCtD
Brimonidine—Depression—Topiramate—obesity	0.000229	0.00129	CcSEcCtD
Brimonidine—Infection—Bupropion—obesity	0.000228	0.00129	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Sibutramine—obesity	0.000228	0.00128	CcSEcCtD
Brimonidine—Shock—Bupropion—obesity	0.000226	0.00128	CcSEcCtD
Brimonidine—Pain—Sibutramine—obesity	0.000225	0.00127	CcSEcCtD
Brimonidine—Nervous system disorder—Bupropion—obesity	0.000225	0.00127	CcSEcCtD
Brimonidine—Tachycardia—Bupropion—obesity	0.000224	0.00127	CcSEcCtD
Brimonidine—Skin disorder—Bupropion—obesity	0.000223	0.00126	CcSEcCtD
Brimonidine—Conjunctivitis—Topiramate—obesity	0.000223	0.00126	CcSEcCtD
Brimonidine—Sinusitis—Topiramate—obesity	0.000215	0.00121	CcSEcCtD
Brimonidine—Hypotension—Bupropion—obesity	0.000215	0.00121	CcSEcCtD
Brimonidine—ADRA2A—adrenal gland—obesity	0.00021	0.0279	CbGeAlD
Brimonidine—Bradycardia—Topiramate—obesity	0.00021	0.00118	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Bupropion—obesity	0.000209	0.00118	CcSEcCtD
Brimonidine—Insomnia—Bupropion—obesity	0.000208	0.00117	CcSEcCtD
Brimonidine—Rhinitis—Topiramate—obesity	0.000207	0.00117	CcSEcCtD
Brimonidine—Paraesthesia—Bupropion—obesity	0.000206	0.00116	CcSEcCtD
Brimonidine—ADRA2C—liver—obesity	0.000206	0.0273	CbGeAlD
Brimonidine—Dyspnoea—Bupropion—obesity	0.000205	0.00116	CcSEcCtD
Brimonidine—Pharyngitis—Topiramate—obesity	0.000205	0.00115	CcSEcCtD
Brimonidine—Somnolence—Bupropion—obesity	0.000204	0.00115	CcSEcCtD
Brimonidine—Dyspepsia—Bupropion—obesity	0.000202	0.00114	CcSEcCtD
Brimonidine—Hypersensitivity—Orlistat—obesity	0.000201	0.00113	CcSEcCtD
Brimonidine—Visual impairment—Topiramate—obesity	0.000199	0.00112	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Bupropion—obesity	0.000198	0.00112	CcSEcCtD
Brimonidine—Fatigue—Bupropion—obesity	0.000198	0.00112	CcSEcCtD
Brimonidine—Pain—Bupropion—obesity	0.000197	0.00111	CcSEcCtD
Brimonidine—Asthenia—Orlistat—obesity	0.000195	0.0011	CcSEcCtD
Brimonidine—Hypersensitivity—Sibutramine—obesity	0.000194	0.0011	CcSEcCtD
Brimonidine—Pruritus—Orlistat—obesity	0.000193	0.00109	CcSEcCtD
Brimonidine—Eye disorder—Topiramate—obesity	0.000193	0.00109	CcSEcCtD
Brimonidine—Cardiac disorder—Topiramate—obesity	0.000191	0.00108	CcSEcCtD
Brimonidine—Flushing—Topiramate—obesity	0.000191	0.00108	CcSEcCtD
Brimonidine—Asthenia—Sibutramine—obesity	0.000189	0.00107	CcSEcCtD
Brimonidine—Angiopathy—Topiramate—obesity	0.000187	0.00105	CcSEcCtD
Brimonidine—Pruritus—Sibutramine—obesity	0.000187	0.00105	CcSEcCtD
Brimonidine—Immune system disorder—Topiramate—obesity	0.000186	0.00105	CcSEcCtD
Brimonidine—Mediastinal disorder—Topiramate—obesity	0.000186	0.00105	CcSEcCtD
Brimonidine—ADRA2A—endocrine gland—obesity	0.000183	0.0242	CbGeAlD
Brimonidine—Mental disorder—Topiramate—obesity	0.000181	0.00102	CcSEcCtD
Brimonidine—Dizziness—Orlistat—obesity	0.00018	0.00102	CcSEcCtD
Brimonidine—Erythema—Topiramate—obesity	0.000179	0.00101	CcSEcCtD
Brimonidine—Dysgeusia—Topiramate—obesity	0.000176	0.000991	CcSEcCtD
Brimonidine—Dizziness—Sibutramine—obesity	0.000174	0.000983	CcSEcCtD
Brimonidine—Rash—Orlistat—obesity	0.000172	0.000969	CcSEcCtD
Brimonidine—Dermatitis—Orlistat—obesity	0.000172	0.000968	CcSEcCtD
Brimonidine—Headache—Orlistat—obesity	0.000171	0.000963	CcSEcCtD
Brimonidine—Hypersensitivity—Bupropion—obesity	0.000169	0.000955	CcSEcCtD
Brimonidine—Vision blurred—Topiramate—obesity	0.000169	0.000954	CcSEcCtD
Brimonidine—Rash—Sibutramine—obesity	0.000166	0.000938	CcSEcCtD
Brimonidine—Dermatitis—Sibutramine—obesity	0.000166	0.000937	CcSEcCtD
Brimonidine—Headache—Sibutramine—obesity	0.000165	0.000932	CcSEcCtD
Brimonidine—Asthenia—Bupropion—obesity	0.000165	0.00093	CcSEcCtD
Brimonidine—Pruritus—Bupropion—obesity	0.000163	0.000917	CcSEcCtD
Brimonidine—Nausea—Orlistat—obesity	0.000162	0.000913	CcSEcCtD
Brimonidine—Syncope—Topiramate—obesity	0.000161	0.000907	CcSEcCtD
Brimonidine—Palpitations—Topiramate—obesity	0.000159	0.000894	CcSEcCtD
Brimonidine—Loss of consciousness—Topiramate—obesity	0.000158	0.000889	CcSEcCtD
Brimonidine—Nausea—Sibutramine—obesity	0.000157	0.000883	CcSEcCtD
Brimonidine—Cough—Topiramate—obesity	0.000157	0.000883	CcSEcCtD
Brimonidine—Hypertension—Topiramate—obesity	0.000155	0.000874	CcSEcCtD
Brimonidine—Myalgia—Topiramate—obesity	0.000153	0.000862	CcSEcCtD
Brimonidine—Chest pain—Topiramate—obesity	0.000153	0.000862	CcSEcCtD
Brimonidine—Arthralgia—Topiramate—obesity	0.000153	0.000862	CcSEcCtD
Brimonidine—Anxiety—Topiramate—obesity	0.000152	0.000859	CcSEcCtD
Brimonidine—Dizziness—Bupropion—obesity	0.000152	0.000857	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000152	0.000856	CcSEcCtD
Brimonidine—Discomfort—Topiramate—obesity	0.000151	0.000851	CcSEcCtD
Brimonidine—Dry mouth—Topiramate—obesity	0.000149	0.000843	CcSEcCtD
Brimonidine—Oedema—Topiramate—obesity	0.000146	0.000826	CcSEcCtD
Brimonidine—Infection—Topiramate—obesity	0.000145	0.00082	CcSEcCtD
Brimonidine—Rash—Bupropion—obesity	0.000145	0.000817	CcSEcCtD
Brimonidine—Dermatitis—Bupropion—obesity	0.000145	0.000817	CcSEcCtD
Brimonidine—Shock—Topiramate—obesity	0.000144	0.000813	CcSEcCtD
Brimonidine—Headache—Bupropion—obesity	0.000144	0.000812	CcSEcCtD
Brimonidine—Nervous system disorder—Topiramate—obesity	0.000144	0.00081	CcSEcCtD
Brimonidine—Tachycardia—Topiramate—obesity	0.000143	0.000806	CcSEcCtD
Brimonidine—Skin disorder—Topiramate—obesity	0.000142	0.000802	CcSEcCtD
Brimonidine—Hypotension—Topiramate—obesity	0.000137	0.000772	CcSEcCtD
Brimonidine—Nausea—Bupropion—obesity	0.000137	0.00077	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Topiramate—obesity	0.000133	0.000752	CcSEcCtD
Brimonidine—Insomnia—Topiramate—obesity	0.000132	0.000747	CcSEcCtD
Brimonidine—Paraesthesia—Topiramate—obesity	0.000131	0.000742	CcSEcCtD
Brimonidine—Dyspnoea—Topiramate—obesity	0.000131	0.000736	CcSEcCtD
Brimonidine—Somnolence—Topiramate—obesity	0.00013	0.000734	CcSEcCtD
Brimonidine—Dyspepsia—Topiramate—obesity	0.000129	0.000727	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Topiramate—obesity	0.000126	0.000713	CcSEcCtD
Brimonidine—Fatigue—Topiramate—obesity	0.000126	0.000712	CcSEcCtD
Brimonidine—Pain—Topiramate—obesity	0.000125	0.000706	CcSEcCtD
Brimonidine—Hypersensitivity—Topiramate—obesity	0.000108	0.000608	CcSEcCtD
Brimonidine—Asthenia—Topiramate—obesity	0.000105	0.000593	CcSEcCtD
Brimonidine—Pruritus—Topiramate—obesity	0.000104	0.000584	CcSEcCtD
Brimonidine—Dizziness—Topiramate—obesity	9.68e-05	0.000546	CcSEcCtD
Brimonidine—Rash—Topiramate—obesity	9.23e-05	0.000521	CcSEcCtD
Brimonidine—Dermatitis—Topiramate—obesity	9.22e-05	0.00052	CcSEcCtD
Brimonidine—Headache—Topiramate—obesity	9.17e-05	0.000517	CcSEcCtD
Brimonidine—Nausea—Topiramate—obesity	8.7e-05	0.000491	CcSEcCtD
Brimonidine—ADRA2C—Signaling Pathways—FOXO3—obesity	1.15e-05	8.89e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRB1—obesity	1.15e-05	8.89e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF2—obesity	1.15e-05	8.88e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADRB2—obesity	1.15e-05	8.87e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—RHOA—obesity	1.15e-05	8.84e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CG—obesity	1.14e-05	8.81e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GNAS—obesity	1.14e-05	8.81e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3R1—obesity	1.14e-05	8.75e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CD36—obesity	1.13e-05	8.74e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SOCS1—obesity	1.13e-05	8.74e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GHRL—obesity	1.13e-05	8.71e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PARP1—obesity	1.13e-05	8.71e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CD—obesity	1.12e-05	8.66e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DRD4—obesity	1.12e-05	8.63e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SOCS3—obesity	1.12e-05	8.63e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APOB—obesity	1.12e-05	8.62e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—PIK3CA—obesity	1.11e-05	8.58e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GNB3—obesity	1.1e-05	8.45e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCL5—obesity	1.09e-05	8.42e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—POMC—obesity	1.09e-05	8.39e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—F2—obesity	1.09e-05	8.36e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PRKCB—obesity	1.09e-05	8.36e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—TYK2—obesity	1.08e-05	8.33e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—COMT—obesity	1.08e-05	8.32e-05	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CB—obesity	1.08e-05	8.31e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF2—obesity	1.08e-05	8.3e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—MTHFR—obesity	1.08e-05	8.28e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—RHOA—obesity	1.07e-05	8.26e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CNR1—obesity	1.07e-05	8.24e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LPL—obesity	1.07e-05	8.23e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GNAS—obesity	1.07e-05	8.23e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARGC1A—obesity	1.07e-05	8.21e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GNB3—obesity	1.07e-05	8.21e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3R1—obesity	1.06e-05	8.18e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FOXO1—obesity	1.06e-05	8.18e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—HMOX1—obesity	1.06e-05	8.17e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RPS6KB1—obesity	1.06e-05	8.16e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPARA—obesity	1.06e-05	8.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TCF7L2—obesity	1.05e-05	8.1e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CB—obesity	1.05e-05	8.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT2—obesity	1.05e-05	8.06e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APOB—obesity	1.05e-05	8.06e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DRD2—obesity	1.04e-05	8.04e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—PIK3CA—obesity	1.04e-05	8.02e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CG—obesity	1.04e-05	8e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GNAS—obesity	1.04e-05	7.99e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTPN1—obesity	1.03e-05	7.96e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GCG—obesity	1.03e-05	7.96e-05	CbGpPWpGaD
Brimonidine—AOX1—Disease—IL6—obesity	1.02e-05	7.88e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AGT—obesity	1.02e-05	7.87e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCL5—obesity	1.02e-05	7.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—APOB—obesity	1.02e-05	7.83e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CD—obesity	1.01e-05	7.75e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—APOE—obesity	1e-05	7.71e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LPL—obesity	9.99e-06	7.69e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TGFB1—obesity	9.94e-06	7.65e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CAV1—obesity	9.92e-06	7.64e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FOXO1—obesity	9.92e-06	7.64e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RPS6KB1—obesity	9.9e-06	7.62e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—APOA1—obesity	9.9e-06	7.62e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—POMC—obesity	9.89e-06	7.62e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PRL—obesity	9.86e-06	7.6e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PRKCD—obesity	9.85e-06	7.59e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CB—obesity	9.8e-06	7.55e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STK11—obesity	9.72e-06	7.49e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—LPL—obesity	9.7e-06	7.47e-05	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CA—obesity	9.68e-06	7.45e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCL2—obesity	9.68e-06	7.45e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HTR2A—obesity	9.64e-06	7.42e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—C3—obesity	9.63e-06	7.41e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PLG—obesity	9.61e-06	7.4e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—RHOA—obesity	9.6e-06	7.39e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT2—obesity	9.51e-06	7.32e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3R1—obesity	9.5e-06	7.31e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GPX1—obesity	9.47e-06	7.29e-05	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT1—obesity	9.44e-06	7.27e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FOXO3—obesity	9.38e-06	7.22e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRB2—obesity	9.36e-06	7.21e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CD36—obesity	9.22e-06	7.1e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SOCS1—obesity	9.21e-06	7.1e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PRKCD—obesity	9.2e-06	7.09e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS2—obesity	9.16e-06	7.05e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AGT—obesity	9.15e-06	7.04e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CD—obesity	9.13e-06	7.03e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT1—obesity	9.1e-06	7.01e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SOCS3—obesity	9.1e-06	7.01e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CG—obesity	9.04e-06	6.96e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HTR2A—obesity	9.01e-06	6.94e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—C3—obesity	8.99e-06	6.93e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LEP—obesity	8.96e-06	6.9e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APOE—obesity	8.96e-06	6.9e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GNB3—obesity	8.91e-06	6.86e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CAV1—obesity	8.88e-06	6.84e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APOA1—obesity	8.86e-06	6.82e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—TYK2—obesity	8.79e-06	6.77e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CB—obesity	8.77e-06	6.75e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF2—obesity	8.75e-06	6.74e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MTHFR—obesity	8.74e-06	6.73e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPARG—obesity	8.72e-06	6.72e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—RHOA—obesity	8.71e-06	6.71e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GNAS—obesity	8.68e-06	6.68e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3R1—obesity	8.62e-06	6.64e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—POMC—obesity	8.6e-06	6.62e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARA—obesity	8.57e-06	6.6e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ESR1—obesity	8.56e-06	6.59e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS2—obesity	8.56e-06	6.59e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—INS—obesity	8.55e-06	6.59e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AGT—obesity	8.54e-06	6.58e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT1—obesity	8.5e-06	6.55e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APOB—obesity	8.5e-06	6.54e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CA—obesity	8.46e-06	6.51e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—F2—obesity	8.45e-06	6.51e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PRKCB—obesity	8.45e-06	6.51e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LEP—obesity	8.37e-06	6.45e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APOE—obesity	8.37e-06	6.45e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—BAD—obesity	8.35e-06	6.43e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AGT—obesity	8.3e-06	6.39e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCL5—obesity	8.3e-06	6.39e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CAV1—obesity	8.29e-06	6.39e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APOA1—obesity	8.28e-06	6.37e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—APOE—obesity	8.13e-06	6.26e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LPL—obesity	8.11e-06	6.25e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CG—obesity	8.09e-06	6.23e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CAV1—obesity	8.06e-06	6.21e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FOXO1—obesity	8.05e-06	6.2e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RPS6KB1—obesity	8.04e-06	6.19e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—APOA1—obesity	8.04e-06	6.19e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS1—obesity	8e-06	6.16e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ESR1—obesity	7.99e-06	6.16e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CB—obesity	7.96e-06	6.13e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CD—obesity	7.94e-06	6.12e-05	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AKT1—obesity	7.91e-06	6.09e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PRKCB—obesity	7.9e-06	6.08e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—F2—obesity	7.9e-06	6.08e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALB—obesity	7.84e-06	6.04e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—BAD—obesity	7.8e-06	6.01e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—POMC—obesity	7.7e-06	5.93e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—INS—obesity	7.66e-06	5.9e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CG—obesity	7.56e-06	5.82e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCL2—obesity	7.53e-06	5.8e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—NOS3—obesity	7.5e-06	5.78e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3R1—obesity	7.5e-06	5.78e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PRKCD—obesity	7.47e-06	5.76e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS1—obesity	7.47e-06	5.75e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF1—obesity	7.41e-06	5.7e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT2—obesity	7.4e-06	5.7e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CG—obesity	7.34e-06	5.65e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HTR2A—obesity	7.31e-06	5.63e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—C3—obesity	7.3e-06	5.63e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—POMC—obesity	7.19e-06	5.54e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—INS—obesity	7.15e-06	5.51e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CD—obesity	7.11e-06	5.48e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARG—obesity	7.08e-06	5.46e-05	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CA—obesity	7.04e-06	5.42e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCL2—obesity	7.04e-06	5.42e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SERPINE1—obesity	7.03e-06	5.42e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—POMC—obesity	6.99e-06	5.38e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS2—obesity	6.95e-06	5.35e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—INS—obesity	6.95e-06	5.35e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AGT—obesity	6.94e-06	5.34e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CB—obesity	6.92e-06	5.33e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1—obesity	6.92e-06	5.33e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT2—obesity	6.91e-06	5.32e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT1—obesity	6.91e-06	5.32e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS2—obesity	6.86e-06	5.28e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TYK2—obesity	6.84e-06	5.27e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LEP—obesity	6.8e-06	5.24e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APOE—obesity	6.8e-06	5.24e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RHOA—obesity	6.78e-06	5.22e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CAV1—obesity	6.74e-06	5.19e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APOA1—obesity	6.72e-06	5.18e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOS3—obesity	6.71e-06	5.17e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3R1—obesity	6.71e-06	5.17e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CD—obesity	6.64e-06	5.12e-05	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CA—obesity	6.58e-06	5.07e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SERPINE1—obesity	6.57e-06	5.06e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ESR1—obesity	6.49e-06	5e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CD—obesity	6.45e-06	4.97e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—F2—obesity	6.41e-06	4.94e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PRKCB—obesity	6.41e-06	4.94e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CA—obesity	6.4e-06	4.93e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TYK2—obesity	6.39e-06	4.92e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALB—obesity	6.37e-06	4.91e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RHOA—obesity	6.34e-06	4.88e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—BAD—obesity	6.34e-06	4.88e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3R1—obesity	6.27e-06	4.83e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOS3—obesity	6.27e-06	4.83e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MTOR—obesity	6.2e-06	4.77e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CB—obesity	6.2e-06	4.77e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CG—obesity	6.14e-06	4.73e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—NOS3—obesity	6.09e-06	4.69e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3R1—obesity	6.09e-06	4.69e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS1—obesity	6.07e-06	4.67e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CA—obesity	5.97e-06	4.6e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—POMC—obesity	5.84e-06	4.5e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—INS—obesity	5.81e-06	4.47e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MTOR—obesity	5.79e-06	4.46e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CB—obesity	5.79e-06	4.46e-05	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT1—obesity	5.75e-06	4.43e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCL2—obesity	5.72e-06	4.4e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—obesity	5.66e-06	4.36e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CB—obesity	5.62e-06	4.33e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1—obesity	5.62e-06	4.33e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT2—obesity	5.62e-06	4.32e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS2—obesity	5.57e-06	4.29e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CD—obesity	5.4e-06	4.15e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MMP9—obesity	5.39e-06	4.15e-05	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT1—obesity	5.37e-06	4.14e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CA—obesity	5.34e-06	4.12e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SERPINE1—obesity	5.34e-06	4.11e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—obesity	5.29e-06	4.07e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK8—obesity	5.24e-06	4.03e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT1—obesity	5.22e-06	4.02e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TYK2—obesity	5.19e-06	4e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RHOA—obesity	5.15e-06	3.96e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3R1—obesity	5.09e-06	3.92e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOS3—obesity	5.09e-06	3.92e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MMP9—obesity	5.03e-06	3.88e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK8—obesity	4.89e-06	3.77e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT1—obesity	4.88e-06	3.76e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CA—obesity	4.85e-06	3.74e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STAT3—obesity	4.79e-06	3.69e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CB—obesity	4.7e-06	3.62e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MTOR—obesity	4.7e-06	3.62e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STAT3—obesity	4.47e-06	3.45e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—obesity	4.45e-06	3.43e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFB1—obesity	4.44e-06	3.42e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT1—obesity	4.37e-06	3.36e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—obesity	4.3e-06	3.31e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CA—obesity	4.22e-06	3.25e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—obesity	4.16e-06	3.2e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFB1—obesity	4.15e-06	3.19e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP9—obesity	4.09e-06	3.15e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK8—obesity	3.98e-06	3.06e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT1—obesity	3.96e-06	3.05e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CA—obesity	3.78e-06	2.91e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT3—obesity	3.63e-06	2.8e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CA—obesity	3.53e-06	2.72e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKT1—obesity	3.45e-06	2.66e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CA—obesity	3.43e-06	2.64e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—obesity	3.38e-06	2.6e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFB1—obesity	3.37e-06	2.59e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—obesity	3.35e-06	2.58e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—obesity	3.13e-06	2.41e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT1—obesity	3.09e-06	2.38e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT1—obesity	2.88e-06	2.22e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CA—obesity	2.87e-06	2.21e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKT1—obesity	2.8e-06	2.16e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—obesity	2.54e-06	1.95e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT1—obesity	2.34e-06	1.8e-05	CbGpPWpGaD
